XORTX Therapeutics Inc. - Common Shares, no par value per share (XRTX) Institutional Ownership

13F Institutional Holders and Ownership History from Q4 2023 to Q4 2025

Type / Class
Equity / Common Shares, no par value per share
Symbol
XRTX on Nasdaq
Shares outstanding
5,782,525
Price per share
$0.44
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
230,697
Total reported value
$123,562
% of total 13F portfolios
0%
Share change
+130,039
Value change
+$42,216
Number of holders
6
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of XORTX Therapeutics Inc. - Common Shares, no par value per share (XRTX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Lincoln Alternative Strategies LLC 9.9% $498,049 572,470 Lincoln Alternative Strategies LLC 23 Oct 2025
ARMISTICE CAPITAL, LLC 5% -50% $183,372 -$173,839 178,031 -49% Armistice Capital, LLC 31 Mar 2025

As of 31 Dec 2025, 6 institutional investors reported holding 230,697 shares of XORTX Therapeutics Inc. - Common Shares, no par value per share (XRTX). This represents 4% of the company’s total 5,782,525 outstanding shares.

Institutional Holders of XORTX Therapeutics Inc. - Common Shares, no par value per share (XRTX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 230,697 $123,562 +$42,216 $0.56 6
2025 Q3 100,658 $81,474 +$27,883 $0.81 5
2025 Q2 64,632 $60,190 +$59,767 $0.92 6
2025 Q1 451 $416 -$323,581 $0.91 2
2024 Q4 286,964 $324,394 +$295,595 $1.13 6
2024 Q3 24,660 $41,135 +$12,446 $1.64 7
2024 Q2 15,243 $29,237 -$34,492 $1.90 5
2024 Q1 16,678 $65,974 -$160,558,988 $3.84 4
2023 Q4 2,764,045 $160,623,303 +$160,623,303 $2.31 4